Literature DB >> 19095294

Wnt pathway and IL-17: novel regulators of joint remodeling in rheumatic diseases. Looking beyond the RANK-RANKL-OPG axis.

Dimitrios Daoussis1, Andrew P Andonopoulos, Stamatis-Nick C Liossis.   

Abstract

OBJECTIVES: During the last decade research has focused on the RANK-RANKL-OPG (Receptor Activator of Nuclear factor KappaB-Receptor Activator of Nuclear factor KappaB Ligand-Osteoprotegerin) pathway that is currently considered the final common route to bone and joint remodeling. The potential role of novel additional mediators has been highlighted by several reports. This review focuses on the recent information about the pathophysiology of the Wingless (Wnt) pathway and interleukin-17 (IL-17) in relation of their role in bone and joint remodeling.
METHODS: An extensive internet search was performed (PubMed) from 1998 and onward using the following keywords: Wnt, bone remodeling, bone, rheumatic diseases, rheumatoid arthritis, IL-17, Th17, osteoblastogenesis, and osteoclastogenesis.
RESULTS: Several members of the Wnt pathway play an important role in bone remodeling. Recent experimental data indicate a key role for Dickkopf-1, a soluble inhibitor of the Wnt pathway, in bone remodeling. Increased Dickkopf-1 levels are linked to bone resorption and decreased levels to new bone formation. Low-density lipoprotein receptor-related protein-5, the main receptor that mediates Wnt signaling, plays a critical role in bone mass regulation. Gain-of-function mutations of lipoprotein receptor-related protein-5 cause high bone mass phenotypes, whereas loss-of-function mutations are linked to severe osteoporosis. IL-17 is a proinflammatory cytokine that is produced by a recently described T-cell subset, known as Th17 cells. Evidence suggests that IL-17 is a critical mediator of joint destruction in animal models of arthritis. IL-17 blockade has beneficial effects on murine arthritis, a fact that points to the direction of this cytokine as a potential therapeutic target in human inflammatory arthritides as well.
CONCLUSIONS: The available data suggest that mediators in these 2 biologic systems are critical in joint remodeling and may be appropriate targets in the treatment of bone and joint abnormalities that characterize a variety of inflammatory arthritides and bone diseases. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19095294     DOI: 10.1016/j.semarthrit.2008.10.008

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  19 in total

1.  Unanswered questions in the management of axial spondyloarthritis: an opinion piece.

Authors:  Xenofon Baraliakos; Atul Deodhar
Journal:  Clin Rheumatol       Date:  2014       Impact factor: 2.980

2.  High dose of TNF-α suppressed osteogenic differentiation of human dental pulp stem cells by activating the Wnt/β-catenin signaling.

Authors:  Zhenjie Qin; Zhixiu Fang; Lei Zhao; Jing Chen; Yuanteng Li; Guangyun Liu
Journal:  J Mol Histol       Date:  2015-06-27       Impact factor: 2.611

3.  DKK-1 Is Underexpressed in Mesenchymal Stem Cells from Patients with Ankylosing Spondylitis and Further Downregulated by IL-17.

Authors:  Dimitrios Daoussis; Anastasia Kanellou; Elias Panagiotopoulos; Dionysios Papachristou
Journal:  Int J Mol Sci       Date:  2022-06-15       Impact factor: 6.208

4.  Comparison of peripheral quantitative computed tomography forearm bone density versus DXA in rheumatoid arthritis patients and controls.

Authors:  B Juhász; K Gulyás; Á Horváth; Z Pethő; H P Bhattoa; A Váncsa; É Szekanecz; C Horváth; J Kocsis; Z Horváth; K Hodosi; S Szántó; G Szűcs; Z Szekanecz
Journal:  Osteoporos Int       Date:  2016-12-10       Impact factor: 4.507

5.  Evaluating the role of serum sclerostin as an indicator of activity and damage in Egyptian patients with rheumatoid arthritis: university hospital experience.

Authors:  Ahmed Fayed; Rasmia Elgohary; Mary Fawzy
Journal:  Clin Rheumatol       Date:  2019-12-21       Impact factor: 2.980

6.  Effects of 1-year anti-TNF-α therapies on bone mineral density and bone biomarkers in rheumatoid arthritis and ankylosing spondylitis.

Authors:  Katalin Gulyás; Ágnes Horváth; Edit Végh; Anita Pusztai; Ágnes Szentpétery; Zsófia Pethö; Andrea Váncsa; Nóra Bodnár; Péter Csomor; Attila Hamar; Levente Bodoki; Harjit Pal Bhattoa; Balázs Juhász; Zoltán Nagy; Katalin Hodosi; Tamás Karosi; Oliver FitzGerald; Gabriella Szücs; Zoltán Szekanecz; Szilvia Szamosi; Sándor Szántó
Journal:  Clin Rheumatol       Date:  2019-09-14       Impact factor: 2.980

Review 7.  The Interrelationship Between Diabetes, IL-17 and Bone Loss.

Authors:  Zhen Huang; Xiyan Pei; Dana T Graves
Journal:  Curr Osteoporos Rep       Date:  2020-02       Impact factor: 5.163

Review 8.  IL-17 in Rheumatoid Arthritis and Precision Medicine: From Synovitis Expression to Circulating Bioactive Levels.

Authors:  Marie Robert; Pierre Miossec
Journal:  Front Med (Lausanne)       Date:  2019-01-14

9.  Serum dickkopf-1 level in postmenopausal females: correlation with bone mineral density and serum biochemical markers.

Authors:  Sahar Fathi Ahmed; Neveen Fouda; Amal Ahmed Abbas
Journal:  J Osteoporos       Date:  2013-06-27

10.  IL-17 cytokines in bone healing of diabetic Charcot arthropathy patients: a prospective 2 year follow-up study.

Authors:  Agnetha Folestad; Martin Ålund; Susanne Asteberg; Jesper Fowelin; Ylva Aurell; Jan Göthlin; Jean Cassuto
Journal:  J Foot Ankle Res       Date:  2015-08-18       Impact factor: 2.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.